Skip to main content

Table 2 Treatment-related adverse events

From: A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint

Event-no.(%) Cohort 1 (N = 7) Cohort 2 (N = 10)
All grades Grade 3 or 4 All grades Grade 3 or 4
Any event 7 (100) 3 (43) 10 (100) 5 (50)
Injection Site Reactions**     
GVAX 7 (100) 0 8 (80) 0
Guadecitabine 5 (71) 0 7 (70) 0
Generalized Symptoms     
Fatigue 5 (71) 0 8 (80) 3 (30)
Fever/Chills 3 (43) 0 2 (20) 0
Myalgia 2 (29) 0 1 (10) 0
Headache 1 (14) 0 3 (30) 0
Flu-like illness 0 0 1 (10) 0
Dizziness 1 (14) 0 0 0
Gastrointestinal     
Constipation 2 (29) 0 2 (20) 0
Nausea/vomiting 3 (43) 0 2 (20) 0
Diarrhea 0 0 1 (10) 0
Flatulence 1 (14) 0 0 0
Hematologic     
Neutropenia 3 (43) 3 (43) 4 (40) 4 (40)
Leukopenia 0 0 1 (10) 1 (10)
Anemia 1 (14) 0 0 0
Dermatologic     
Rash/Pruritis 0 0 2 (20) 0
Hives 1 (14) 0 0 0
Other     
Cough 1 (14) 0 0 0
Warmth, thighs 1 (14) 0 0 0
  1. *Events were counted once for each patient using the highest grading
  2. **Includes erythema, induration, pruritis, hyperpigmentation, tenderness
\